Filed in archive
Venture Capital
by Greg Cruey on April 2, 2008
ProGenTech, a life science company with offices in Shanghai, Suzhou and Emeryville California, announced last week that it had received US$21 million in venture capital funding from two sources.
According to East Bay Business Times the two funding sources were Bay City Capital of San Francisco and DT Capital of Shanghai.
A press release said that ProGenTech makes "a contamination free, cassette based automated nucleic acid purification systems." I'd probably have to see a picture and take a few biochemistry classes to be able to explain exactly what that means. But the funding is part of a growing trend of venture capital involvement in the medical technologies industry in China.
ProGenTech has been around since 2005 and has about 40 employees.
According to East Bay Business Times the two funding sources were Bay City Capital of San Francisco and DT Capital of Shanghai.
A press release said that ProGenTech makes "a contamination free, cassette based automated nucleic acid purification systems." I'd probably have to see a picture and take a few biochemistry classes to be able to explain exactly what that means. But the funding is part of a growing trend of venture capital involvement in the medical technologies industry in China.
ProGenTech has been around since 2005 and has about 40 employees.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/118961
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Shanghai-Based ProGenTech Draws $21m in VC Funds:
|
Rating: 6.00 out of 2 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
